Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
Amarantus BioScience Holdings, Inc.
655 Montgomery Street
San Francisco, CA 94111
Phone: (415) 688-4484
Fax: (408) 852-4427
Jenene Thomas Communications, LLC
Jenene Thomas, Investor Relations and Corporate Communications Advisor
Phone: (908) 938-1475
Forward Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.